FDA Accepts for Review Takeda’s Entyvio SC Form for Crohn’s

Takeda Pharmaceutical said on September 13 that the US FDA has accepted for review its application seeking approval for a subcutaneous formulation of its IBD drug Entyvio (vedolizumab) for Crohn’s disease maintenance therapy. The biologics license application was filed for...read more